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Intermolecular biparatopic trapping of ErbB2
prevents compensatory activation of PI3K/AKT
via RAS–p110 crosstalk
Rastislav Tamaskovic1,*, Martin Schwill1,*, Gabriela Nagy-Davidescu1, Christian Jost1,w, Dagmar C. Schaefer2,
Wouter P.R. Verdurmen1, Jonas V. Schaefer1, Annemarie Honegger1 & Andreas Plu¨ckthun1
Compensatory mechanisms, such as relief of AKT-ErbB3-negative feedback, are known to
desensitize ErbB2-dependent tumours to targeted therapy. Here we describe an adaptation
mechanism leading to reactivation of the PI3K/AKT pathway during trastuzumab treatment,
which occurs independently of ErbB3 re-phosphorylation. This signalling bypass of
phospho-ErbB3 operates in ErbB2-overexpressing cells via RAS-PI3K crosstalk and is
attributable to active ErbB2 homodimers. As demonstrated by dual blockade of ErbB2/RAS
and ErbB3 by means of pharmacological inhibition, RNA interference or by speciﬁc protein
binders obstructing the RAS–p110a interaction, both routes must be blocked to prevent
reactivation of the PI3K/AKT pathway. Applying these general principles, we developed
biparatopic designed ankyrin repeat proteins (DARPins) trapping ErbB2 in a dimerization-
incompetent state, which entail pan-ErbB inhibition and a permanent OFF state in the
oncogenic signalling, thereby triggering extensive apoptosis in ErbB2-addicted tumours. Thus,
these novel insights into mechanisms underlying network robustness provide a guide for
overcoming adaptation response to ErbB2/ErbB3-targeted therapy.
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H
uman epidermal growth factor receptor type 2
(ErbB2/HER2/neu) is an orphan receptor adopting a
constitutively extended conformation, which serves as
preferred heterodimerization partner for the ligand-activated
receptors of the ErbB family. The physiological function of this
non-autonomous co-receptor is thus to act primarily as an
ampliﬁer of ErbB signalling1. Nevertheless, under the conditions
of pathological overexpression of ErbB2, as it occurs in 420%
of invasive breast cancer and, to a lesser extent, in gastric or
ovarian cancers2, ErbB2 drives tumorigenesis by spontaneously
forming signalling-competent homodimers, ligand-independent
heterodimers with ErbB3 as well as larger receptor clusters3–6.
As for many other signalling, genetic or metabolic networks,
the ErbB network displays two steady states, that is, bistability,
with ligands transiently switching it from the OFF to the
ON state1. Importantly, the pathological ERBB2 ampliﬁcation
maintains ErbB signalling constitutively active, thereby ﬁxing
the ON state. On the other hand, scale-free networks frequently
evolve reliance on few highly connected nodes, entailing
increased system fragility, as blockade of these central hubs
may cause the entire network to fail. Since malignant diseases
efﬁciently hijack key regulatory elements of the host networks,
these essential hubs can consequently become their ‘Achilles
heels’7. Such a vulnerability of cancer cells, also referred to as
‘oncogene addiction’, may thus provide valuable opportunity for
targeted therapy.
In fact, knockdown of ERBB2 expression triggers apoptosis in
ErbB2-addicted breast cancer cells, while barely having an effect
on cells that do not overexpress this gene8. Analogously, blockade
of the canonical PI3K/AKT/mTOR pathway by small-molecule
inhibitors elicits apoptosis in ErbB2-overexpressing tumour
cells that become addicted also to PI3K signalling, as it conveys
proliferation and survival signals downstream of ErbB2/3
receptors. On the other hand, activating PIK3CA mutations
make the tumours refractory to ErbB2-targeted therapy, and the
response may be restored by co-inhibition of PI3K. Thus, the
possibility to induce tumour cell death by incapacitating critical
nodes of the oncogenic network provides a strong rationale for
targeting the ErbB2/3 oncogenic unit and the downstream
signalling in ErbB2-addicted tumours.
Nevertheless, therapeutic monoclonal antibodies (mAbs)
speciﬁc for ErbB2 target only few epitopes and show rather
poor clinical efﬁcacy in overall long-term survival even as part
of combination therapy regimens. The humanized mAb
trastuzumab is directed against the membrane-proximal
domain IV of ErbB2 (ref. 9). It speciﬁcally inhibits the growth
of breast cancer cell lines addicted to ErbB2, inducing cell
cycle arrest in the G1 phase. Although it was thought earlier
that trastuzumab inhibits ErbB2 signalling, more recent
studies have shown that trastuzumab does not decrease ErbB2
phosphorylation10. Instead, other conceivable mechanisms,
such as dissociation of the ligand-independent ErbB2–ErbB3
heterodimers and consequently dephosphorylation of ErbB3
(ref. 3), are a likely component of the enigmatic mode of
action of trastuzumab in ErbB2-overexpressing tumours.
Another approved ErbB2-binding antibody, pertuzumab,
binds adjacent to the domain II dimerization arm, thereby
disturbing the heterodimerization of ErbB2 with the other
ligand-bound epidermal growth factor receptor (EGFR) family
members11. Pertuzumab thus abrogates solely the ligand-
stimulated growth without affecting the proliferation of tumour
cells driven by ErbB2 overexpression3. Similarly, the antibodies
neutralizing or locking ErbB3 in a tethered conformation have
failed to raise a cytotoxic response in ErbB2-overexpressing
tumours, even though ErbB3 is thought to be indispensable for
ErbB2 oncogenic signalling12–14.
Thus, none of the therapeutic ErbB2/3-targeting mAbs can
fully exploit the addiction to ErbB2 as a tumour’s fragile point for
therapeutic intervention. Apart from the moderate activity,
multiple mechanisms of innate or acquired resistance have also
been described that often neutralize the anti-tumour effect of
trastuzumab15. Acquired resistance arises due to permanent
alterations such as PI3K-activating mutations16, PTEN loss17,
expression of truncated ErbB2 (ref. 15), or long-term adaptive
changes comprising upregulated expression of ErbB family
receptors, cognate RTKs, the respective ligands10, or activation
of co-operating signaling proteins such as Src and CDCP1
(refs 18,19).
A series of tyrosine kinase inhibitors (TKIs) blocking the
ErbB intracellular kinase domains have also been developed,
comprising both reversible and irreversible inhibitors with
speciﬁcity ranging from mono- or dual-speciﬁcity EGFR and
ErbB2 inhibitors to broad-spectrum inhibitors. TKIs elicit
stronger and faster biological responses in vitro than the
highly speciﬁc yet less potent ErbB2-targeting antibodies5.
However, these responses tend to be short-lived because of
rapid emergence of adaptive resistance caused by the reactivation
of ErbB3 signalling20,21 and, consequently, the rebound of
AKT activity due to relief of a negative feedback loop with
the downstream effector FoxO3a22. Such phenomena resulting
from the robustness of ErbB oncogenic signalling also translate
to low clinical efﬁcacy, as was illustrated by rather sobering
data from clinical trials, demonstrating limited activity of
lapatinib either as single agent or in combination with
trastuzumab23–25.
Therefore, other approaches comprising inhibitors of
PI3K/AKT/mTOR pathway, as support of ErbB2 blockade, are
currently being explored, showing encouraging results in
preclinical models and ongoing clinical trials26. These
approaches, based on understanding of the compensatory
mechanisms, are aimed at preventing the emergence of
resistance in tumours, which show an initial response to
blockade of ErbB2. Elucidation of the feedbacks and crosstalks
within signalling pathways underlying the adaptive response thus
hold promise to assist the development of new rational
combination strategies with improved short-term clinical
efﬁcacy27 as well as long-term prevention of development of
acquired resistance.
In the present study, we describe yet another important
adaptation mechanism operating in ErbB2-dependent tumour
cells, which causes the reactivation of the PI3K/AKT pathway
even in the presence of de-phosphorylated ErbB3 receptor. This
mechanism of PI3K/AKT activation bypasses ErbB3 via crosstalk
with the ErbB2-bound small-GTPase RAS, explaining the rapid
desensitization to trastuzumab even in the absence of pathway-
activating mutations. Although some compensatory mechanisms
involving elevated expression of potent activators of RAS such as
EGFR, IGF-1R or c-Met have been described15, thus anticipating
a non-oncogenic function of RAS in mediating resistance to
ErbB2 blockade, the mechanistic explanation is still overdue. Our
ﬁndings provide for the ﬁrst time a direct signalling evidence
linking RAS to evasion of apoptosis in ErbB2-dependent
tumours, particularly under the conditions where ErbB2 does
not become efﬁciently inhibited.
Applying these new insights, we improved upon the traditional
concepts of ErbB2 targeting by designing and mechanistically
dissecting new biparatopic agents that trap ErbB2 in a
dimerization-incompetent state thereby entailing the pan-ErbB
inhibition in ErbB2-addicted tumours. This targeting approach
was shown to disarm all compensatory mechanisms, resulting in
apoptosis induction by enforcing the permanent OFF state in the
ErbB2-driven oncogenic network.
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Results
We constructed biparatopic proteins which speciﬁcally bind
to the ectodomain of ErbB2 (ErbB2_ECD). They are composed
of two designed ankyrin repeat proteins28 (DAPRins). The
biparatopic DARPins with highest anti-tumour activity, referred
to as 6L1G and 9L1H (Supplementary Experimental Procedures),
were fusions of a subdomain I-binding DARPin29 followed
by a subdomain IV-binding DARPin30, which are connected
through a short (Gly4Ser) linker (called ‘L1’). Crystal structures of
the DARPins in complex with their target ErbB2 subdomain31
allowed detailed structural modelling, and together with binding
analyses, revealed that both binding units are intermolecularly
engaged in binding to two ErbB2 receptor molecules on the cell
surface. Such a crosslinking of ErbB2 receptors by biparatopic
DARPins was inferred to induce trapping of ErbB2 (ref. 31),
enforcing a geometry of the ErbB2_ECD that is incompatible with
receptor dimerization or alternative associations, such as tetramers
or higher oligomers6, as well as with trans-activation of receptor
kinase domains32,33. By now dissecting the mechanism of action of
these potent biparatopic agents as compared with ErbB2-targeting
mAbs, we could elucidate compensatory responses upon blockade
of ErbB2/ErbB3, which mediate adaptive resistance in ErbB2-
overexpressing cancers towards mAb treatment.
Apoptosis requires dephosphorylation of both ErbB2 and ErbB3.
Since ErbB2 remained continuously expressed in a panel
of breast cancer cell lines treated with either agent (Fig. 1a–c;
Supplementary Fig. 1A,B), and no substantial increase in
internalization nor degradation of ErbB2 was observed
(Supplementary Fig. 1C–F), we inspected the phosphostatus of
ErbB2 as well as of ErbB3. Treatment with biparatopic DARPins
reduced p-ErbB2 levels, as indicated both by a decline of
total p-Tyr content in immunoprecipitated ErbB2 (Fig. 1a) and a
progressive and uniform reduction of ErbB2 Tyr phosphorylation
at speciﬁc tyrosine phosphorylation sites in the C-terminal tail of
ErbB2 (Y1139, Y1169, Y1221/1222 and Y1248) and kinase
domain (Y877) (Fig. 1b,c; Supplementary Fig. 1A,B) of ErbB2.
By contrast, and in agreement with previous ﬁndings3,10,
the treatment with trastuzumab did not affect total p-ErbB2
level (Fig. 1a) nor the individual p-Tyr sites (Fig. 1b,c;
Supplementary Fig. 1A,B). Consequently, the recruitment of
p-Tyr-binding adaptor proteins such as Grb2, propagating the
cell survival and proliferation signals was impaired by 6L1G but
not by the rather ineffective trastuzumab.
We found ErbB3 expression elevated under all treatment
condition (Fig. 1a,b,d), probably as a result of transcriptional
upregulation of ErbB3 by FoxO3a (cf. Discussion section).
Nevertheless, p-ErbB3 levels declined instantly in response to
ErbB2 blockade by both agents (Fig. 1d; Supplementary
Fig. 1A,B), and in most ErbB2-depended cancer cells there was
a permanent reduction of p-ErbB3. A slow re-phosphorylation of
ErbB3 occurred solely in trastuzumab-treated SKBR3 cells
(Fig. 1d), possibly due to autocrine ligand activation as reported
earlier10. In conclusion, the dephosphorylation of ErbB3 resulting
from ErbB2 blockade correlated with proliferation arrest, as seen
for cytostatic compounds such as trastuzumab, whereas the
induction of cell death also required a complete inhibition of
ErbB2, as achieved by biparatopic DARPins (see below).
Sustained inhibition of AKT is prerequisite for apoptosis. As
shown in Fig. 1e, p-AKT level decreased rapidly upon treatment
with 6L1G and trastuzumab, correlating with the fast
dephosphorylation of ErbB3. Nevertheless, 6L1G caused more
potent and, importantly, a sustained dephosphorylation of AKT.
In contrast, trastuzumab induced a signiﬁcant but transient AKT
dephosphorylation, lasting up to 6–12 h in both BT474 and
SKBR3 cells, and AKT became progressively re-phosphorylated
thereafter. This p-AKT rebound occurred without re-phos-
phorylation of ErbB3 in most cell lines (Fig. 1b), hinting to an
additional upstream stimulus feeding into the AKT pathway.
Since ErbB2 and EGFR are known to signal to the ERK
pathway, we carried out time course analyses of p-ERK in
response to receptor blockade. As shown in Fig. 1f, initiation of
elevated p-ERK levels—notably in the absence of any elevated
p-ErbB2—was detected 15min after addition of trastuzumab or
6L1G. The underlying mechanism of this transient pulse is
unclear, but it may be attributable to the suspended feedback
regulation of RAF/MEK1/ERK leading to ERK stimulation,
particularly in a low PTPase background34. Importantly, after
6–12 h of trastuzumab treatment, ERK phosphorylation returned
to steady-state level in both BT474 and SKBR3 cells, while 6L1G
further reduced the p-ERK level below the basal steady-state level,
thus following the net decline of p-ErbB2.
To assess the relative contributions of the AKT and ERK
pathways as safeguards against apoptosis upon ErbB2 blockade,
we used selective kinase inhibitors as depicted in Fig. 1g. Note
that AKT inhibition by MK2206, but not the MEK1/p-ERK
inhibition by AZD6244, induced upregulation of ErbB3, again
most likely by releasing the AKT-FoxO3a-ErbB3 negative feed-
back. As shown in Fig. 1h,i and Supplementary Fig. 1G, MK2206
exerted a cytostatic activity on BT474 cells, inducing G1 arrest
without signs of apoptosis. Hence, the inhibition of AKT alone is
not sufﬁcient to elicit apoptosis in this model. On the other hand,
inhibition of MEK1 by AZD6244 entirely failed to inhibit cell
growth, but it enhanced signiﬁcantly the anti-proliferative activity
of MK2206. Nevertheless, even the combination of the two
inhibitors could not trigger a full apoptotic response. However, a
potent apoptotic response could be induced by combining
MK2206 with trastuzumab, whereupon the p-ERK level remained
normal (Fig. 1g,i; Supplementary Fig. 1G). By contrast, the
combination with AZD6244 did not enhance the activity of
trastuzumab, probably due to the inability to prevent the p-AKT
rebound. Thus, the ERK pathway exerts merely a modulatory
function and other survival pathways must also operate under the
control of ErbB2/3 oncogenic unit. In contrast, the sustained
inhibition of AKT seems to be the prerequisite for eliciting
apoptosis in ErbB2-overexpressing tumours and signiﬁes the
importance of preventing the p-AKT rebound for the potency of
anti-ErbB2/ErbB3-targeting agents.
Intermolecular trapping of ErbB2 elicits cytotoxic response. To
assess the cytotoxic activity of biparatopic DARPins in vitro, we
treated a panel of ErbB2-overexpressing breast cancer cell lines
(BT474, HCC1419, HCC2218, SKBR3, AU565 and ZR75-30) with
wild-type PI3K activity and a range of EGFR, ErbB3 and PTEN
expression levels (Fig. 2a). All cancer cell lines showed, without
exception, the highest sensitivity to treatment with 6L1G and
9L1H, reﬂecting their cytotoxic activity. In contrast, application of
trastuzumab resulted in an intermediate and highly variable cyto-
static response, and pertuzumab only had minute effects on the
growth of these refractory, ligand-independent ErbB2-over-
expressing cell lines. The qualitative differences between bipar-
atopic DARPins and trastuzumab in the induction of cell death, as
determined by clonogenic assays (Fig. 2b), demonstrates the
irreversible cancer cell damage inﬂicted solely by 6L1G or 9L1H.
The cytotoxic activity of the biparatopic DARPins was strictly
dependent on a bivalent binding mode of both binding
units simultaneously to two ErbB2 receptors, as deduced from
the cell surface binding assays (Supplementary Fig. 2A,B), the
dependency on orientation (Supplementary Fig. 2C,D) and the
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linker length (Supplementary Fig. 2E), indicating also the
importance of the DARPin-induced change in the geometry of
ErbB2_ECD. The anti-proliferative activity of all agents
was dependent solely on ErbB2 binding, as shown by
complete quenching of activity by addition of soluble ErbB2_ECD
as competitor (Supplementary Fig. 2F). Importantly, the
combination of either antibody with a biparatopic DARPin led
to a reduction of the DARPins’ cytotoxic activity (Supplementary
Fig. 2G), indicating the importance of the DARPin-induced
ErbB2 geometry for receptor inhibition.
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Since the cytotoxic effects of the biparatopic agents are by
design conﬁned to tumour cells addicted to overexpression of
ErbB2, non-tumour tissues with low ErbB2 expression should
stay unaffected. We therefore tested the toxicity of DARPins on
fetal human cardiac myocytes and normal human mammary
epithelial cells. As shown in Fig. 2c, none of the DARPins
impaired growth of these primary cells with low ErbB2 receptor
levels, nor did the antibodies pertuzumab or trastuzumab.
However, if trastuzumab was applied together with lapatinib, an
EGFR/ErbB2 kinase inhibitor5 or with a PI3K inhibitor (GDC-
0941), the combination treatment resulted in a substantial growth
arrest or even an extensive cell death, depending on cell type.
Hence, the small-molecule inhibitors appear to not only amplify
the activity of low-potency antibodies on ErbB2-overexpressing
tumours, but also exert toxicity on cells from tissues with low
ErbB2 expression levels, leading inevitably to adverse side effects.
Induction of G1 arrest and apoptosis upon ErbB2 blockade.
The blockade of ErbB2 by 6L1G, 9L1H and trastuzumab, but not
by pertuzumab, provokes cell cycle arrest in G1 phase in most
ErbB2-overexpressing cell lines (Supplementary Fig. 2H). Exam-
ination of the master G1/S-phase transition regulators p27KIP1
and cyclin D1 revealed that their expression levels were inﬂu-
enced by both trastuzumab and 6L1G (Supplementary Fig. 1A),
consistent with the recorded cell cycle proﬁles.
Importantly, the treatment with 6L1G and 9L1H, but none of
the antibodies, yielded an additional peak with sub-G1 DNA
content (Supplementary Fig. 2H,I), a typical hallmark of
apoptosis. The quantiﬁcation of cell populations with fragmented
DNA in terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assays revealed a marked accumulation of
apoptotic cells after application of 6L1G and 9L1H, but not mAb
treatments (Fig. 2d; Supplementary Fig. 2K). Consistent with
these ﬁndings, Annexin V/propidium iodide staining demon-
strated profound phosphatidylserine ﬂipping proportional to the
cytotoxic activity of the interrogated constructs (Fig. 2e). This
early event in the execution of apoptosis has been also observed
by time-lapse microscopy in BT474 cells treated with 6L1G, but
not with trastuzumab (Supplementary Movies 1 and 2). Next,
caspase activation was monitored, distinguishing between intrin-
sic and extrinsic induction of apoptotic pathways by inspecting
initiator caspases 9 or 8, respectively. As shown in Fig. 2f, 6L1G
or GDC-0941 (pictilisib), an inhibitor of PI3K, strongly induced
caspase-9, while tumour necrosis factor-related apoptosis-indu-
cing ligand (TRAIL) expectedly induced caspase-8, and the
effector caspases-3/7 became activated by all apoptotic stimuli.
We thus conclude that the cytotoxic activity of biparatopic
DARPins, despite being nota bene extracellular ligands, is mainly
attributable to activation of the intrinsic apoptotic pathway, and it
occurs speciﬁcally in ErbB2-addicted tumour cells, as also suggested
by the increased expression of the BH3-only pro-apoptotic Bcl-2-
like protein 11 (BIM), a master regulator of apoptosis elicited by
inhibition of EGFR family receptors35 (Fig. 2g).
Efﬁcient ErbB2 blockade induces apoptosis in vivo. The serum
half-life of biparatopic DARPins was extended by N-terminal
PEGylation36,37, which was shown to not affect their maximal
in vitro activity (Supplementary Fig. 3A). To distinguish the
DARPin-mediated anti-tumour activity from complement-
dependent cytolysis or antibody-dependent cellular cytotoxicity
responses, we have chosen the SCID beige mouse strain with a
broad immunodeﬁciency proﬁle and omitted fusions to carriers
such as immunoglobulin Fc domains despite potentially better
pharmacokinetics. The in vivo anti-tumour activity was analysed
on BT474 xenografts that were inoculated orthotopically in the
mammary fat pad of the mice. As shown in Fig. 3a, the targeted
PEGylated constructs became efﬁciently enriched at the tumour
site. Notably, both biparatopic DARPins caused a signiﬁcant
tumour regression (Fig. 3b), while the non-targeted PEGylated
bivalent DARPin (vehicle control) and the phosphate-buffered
saline (PBS) control did not show signiﬁcant effects. Even though
complete tumour remission could not be achieved and post-
treatment tumour regrowth has occurred in most animals,
attributable to insufﬁcient half-life extension by PEGylation, the
anti-tumour activity of biparatopic DARPins in vivo was evident
(Supplementary Fig. 3B,C).
Hematoxylin and eosin staining of sections from the regressing
DARPin-treated tumours revealed large areas of tumour destruc-
tion replaced by ﬁbrous myxoid stroma (Fig. 3c). As shown in
Fig. 3c,d, IHC analysis of the tumours revealed no signiﬁcant
difference in the average ErbB2 expression level per cell among
treatments, while ErbB2 phosphorylation was found signiﬁcantly
reduced after administration of active DARPins. In line with this
observation, the examination of downstream protein kinases
conﬁrmed diminished p-AKT and p-ERK staining in the
successfully treated tumours (Fig. 3c). Tumour growth regression
correlated with the ability to induce apoptosis in vivo, as
manifested by signiﬁcantly stronger TUNEL staining (Fig. 3c,e),
and enrichment of active caspase-3 in the treated tumours. These
data conﬁrm that DARPins retained the ability to induce apoptosis
in vivo, and thus, the achieved tumoricidal activity was attributable
to the same mode of action as in the tissue culture tumour models.
Moreover, measurements of the downstream kinases indicate that
the DARPin-induced apoptosis likely employs the same mechan-
ism as observed in vitro (see above).
Efﬁcient ErbB2 blockade induces apoptosis in 3D tumour models.
Maintaining the breast cancer cell lines in three-dimensional (3D)
Figure 1 | Dynamic signalling responses to ErbB2 blockade. (a) Biparatopic anti-ErbB2 DARPin (6L1G) inhibits phosphorylation of both ErbB2 and ErbB3
while trastuzumab (TZB) attenuates only p-ErbB3. ErbB2-overexpressing cell lines were treated with 100nM of 6L1G or TZB; ErbB2 or ErbB3 was
immunoprecipitated and total phosphotyrosine content (p-Tyr) was determined. Co-IP analysis of Grb2 binding to ErbB2 is also shown. (b) Sustained
inhibition of both AKT and ERK signalling pathways after 6L1G treatment versus transient decrease of p-AKT after 6 h of TZB treatment and consecutive
p-AKT rebound after 72 h. Cancer cell lines were treated as above and whole-cell extracts were analysed. (c–f) Dynamic signalling events induced by TZB
and 6L1G: quantitative western blot time course analysis. Data are means±s.d. of integrated intensities (I.I., cf. Li-COR Odyssey manual), with 100%
referring to I.I. of untreated cells (0 h). (c) Expression of ErbB2 and reduced phosphorylation at speciﬁc Tyr-residues (color-coded (Y877 to Y1248),
*P value versus level at 0 h), (d) expression of ErbB3 and level of p-ErbB3 after 6L1G or TZB treatment (colour-coded signiﬁcance levels; ErbB3 expression
upregulation, *P value versus 0 h; p-ErbB3 Y1289 re-phosphorylation, *P value versus 30min TZB) (e) expression of AKT and level of p-AKT (p-AKT re-
phosphorylation, *P value versus 6 h TZB) (f) expression of ERK1/2 and level of p-ERK1/2 in BT474 and SKBR3 cells (p-ERK dephosphorylation, *P value
versus 0 h). For representative blots see Supplementary Fig. 1A,B. (All statistical analyses are one-way ANOVA on ranks and post hoc Dunnett’s test.) (g–i)
Inhibition of downstream signalling (g) and ensuing effects of proliferation (XTT assay; h) or induction of apoptosis (FACS; i) after 72 h of treatment with
1mM of AKT/PKB inhibitor MK2206, 2 mM MEK1 inhibitor AZD6244 alone or in combination with 100nM TZB or 6L1G (*P value versus MK2206 or as
drawn by brackets in h, two-sided, unpaired Welch’s t-test; Data in i are mean±s.e.m., *P value versus ctrl or as drawn in i, two-sided, unpaired Welch’s t-
test). Similar results were obtained with the AKT inhibitor GDC-0068.
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Figure 2 | Induction of apoptosis upon trapping of ErbB2 by biparatopic agents. (a) Inhibition of proliferation of ErbB2-overexpressing breast cancer cell
lines (XTTassay). Cells were treated for 96 h with 6L1G or 9L1H, non-binding DARPin control (OL1O), trastuzumab (TZB), pertuzumab (PZB) or PBS alone
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cleavage (p89) and BIM expression after 72 h treatment with 100nM of indicated agent.
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cell culture alters proliferation and morphology characteristics
and may affect sensitivity to ErbB2 blockade. In 3D cultures of
BT474 and AU565 cells on a laminin-rich reconstituted basement
membrane (Matrigel), the tumour cells become organized into
acini-like solid spheroid structures resembling a ductal glandular
like architecture38. As shown in Fig. 4a, both DARPins and, to a
lesser extent, trastuzumab abrogated the 3D growth of BT474 and
AU565 spheroids. The proliferation was determined also by 3D
XTT assays (Fig. 4b), and we found that 6L1G showed
consistently stronger effects than trastuzumab in all tested
ErbB2-overexpressing cell lines in 3D cultures. We further
investigated whether the signalling effects of ErbB2 blockade
observed in 2D culture were equivalent also in a 3D matrix.
As shown in Fig. 4c, p-ErbB3 dephosphorylation was observed
after trastuzumab and 6L1G treatment, as was the subsequent
dephosphorylation of downstream p-AKT. Importantly, the
p-AKT rebound was observed 72 h after trastuzumab treatment,
similar to the 2D analysis, in the absence of p-ErbB3
upregulation. In contrast, 6L1G markedly blocked p-ErbB2 and
p-AKT rebound after 72 h. Likewise, marked induction of
apoptosis after 6L1G treatment or the trastuzumab/MK2206
combination (but not trastuzumab alone) was observed under the
3D cell culture conditions.
Inhibition of ErbB2–ErbB3 heterodimerization. The trapping of
ErbB2 by biparatopic agents was proposed to obstruct the cano-
nical interactions with ErbB3 or EGFR31. We therefore
tested this notion by inducing ErbB2–ErbB3 heterodimerization
with heregulin-b1 (HRG) in pretreated BT474 cells and performed
receptor crosslinking on the cell surface with thiol-cleavable
a
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identiﬁed by DAPI using Cell Proﬁler software, and associated TUNEL signals were quantiﬁed and assigned above a threshold (70 units) as TUNEL-positive
(two-sided, unpaired Welch’s t-test).
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3,30-dithiobis[sulfosuccinimidylpropionate] (DTSSP). Co-immuno-
precipitation revealed that DARPins interfered with the
HRG-induced ErbB2–ErbB3 heterodimerization to a similar
extent as pertuzumab (Fig. 5a). Moreover, the ligand-independent
heterodimerization of ErbB2–ErbB3, occurring on and driving
growth of ErbB2-overexpressing tumours3, was also abrogated by
DARPins and by trastuzumab, thereby inducing dephosphorylation
of ErbB3 by uncoupling it from the ErbB2-mediated
transphosphorylation (Fig. 1a,b,d).
Analysis of ErbB2–EGFR heterodimerization was performed
analogously with the corresponding ligand (EGF) on SKBR3 cells,
which express higher levels of EGFR. As shown in Fig. 5a, 6L1G
and 9L1H reduced likewise the ErbB2–EGFR heterodimerization
irrespective of the presence of EGF. Altogether, while anti-ErbB2
mAbs bring about selective blockade of distinct ErbB2
heterodimer complexes, biparatopic DARPins achieve a
pan-ErbB2 inhibition, disengaging the trapped receptors from
all productive homo- and heterodimer interactions.
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Next, we examined the effects of ErbB2-targeting agents
on the morphogenesis in 3D culture, a process that is known
to be under the control of ErbB2-containing heterodimers.
As shown in Fig. 5b, BT474 spheroids underwent morphological
changes upon addition of HRG, manifested by pronounced
budding/branching and invasion of the surrounding matrix.
Again, this phenotype was robustly inhibited by 6L1G and
9L1H, as well as by pertuzumab, whereas trastuzumab had
no effect.
We then investigated the effect of DARPins on cell motility in a
wound-healing assay with SKBR3 cells, high in both EGFR
and ErbB3. As shown in Fig. 5c, both EGF and, in particular,
HRG induced an extensive resealing of scratches in cell
monolayers after a 2-day treatment. The EGF- or HRG-induced
cell migration was reversed by 6L1G and 9L1H but only
retarded by the mAbs, correlating with the speciﬁc ability of
each agent to disrupt the ErbB2 heterodimers (Fig. 5a). Last, a cell
invasion assay using SKBR3 cells stimulated with 1 nM HRG
revealed that biparatopic agents reduced the number of invading
cells more strongly than pertuzumab, which nonetheless
neutralized the effect of HRG (Fig. 5d).
Interplay between ErbB2 and ErbB3 in apoptosis induction. In
a simpliﬁed view, the proliferation of ErbB2-overexpressing
tumour cells is driven predominantly by both ligand-independent
homodimerization of ErbB2 (ref. 4) and heterodimerization with
unliganded ErbB3 (ref. 3), whilst an autocrine ligand stimulation10
has been proposed to confer resistance against ErbB2 blockade
via formation of ligand-containing heterodimers. We used
pertuzumab and the anti-ErbB3 antibody mAb3481, which
abolishes HRG-induced growth (Supplementary Fig. 4A), in
combination with trastuzumab to test whether increased ligand
stimulation accounts for the reactivation of AKT after trastuzumab
treatment. As shown in Fig. 6a,b, neither pertuzumab nor
mAb3481 signiﬁcantly blocked the p-AKT rebound or
potentiated the trastuzumab activity to the level of 6L1G
(Supplementary Fig. 4B), nor did they induce downregulation or
dephosphorylation of ErbB2. We thus conclude that the capability
to induce apoptosis in BT474 cells does not rely on
blocking ligand-induced receptor heterodimerization. Instead, it
is inherent in the obstruction of ErbB2 from participating in
non-liganded homo- or heterodimers, which are promoted by
ErbB2 overexpression.
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receptor was determined by immunoblot analysis. (b) Micrographs show HRG-induced morphogenesis (acini branching) after 12 days of co-treatment
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per acinus. Scale bar, 50mm. (c) Effect of the ErbB2-targeting agents on cell migration. SKBR3 cells were seeded to conﬂuence, and scratch wounds of
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representative micrographs were taken after 48 h. Right, the cell migration was expressed as per cent open area relative to the area at time point 0 h
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on cell invasion induced by HRG. SKBR3 cells pre-seeded on Matrigel in a Boyden-type invasion chamber were treated with the indicated agents (100 nM)
and co-stimulated for 72 h with 1 nM HRG. Data are mean±s.e.m. (*P value versus mock (þHRG) or as drawn, Mann–Whitney test).
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To evaluate the relative contribution of ErbB2 kinase activity to
AKT activation, we used the selective ErbB2 inhibitor ARRY-380.
Since a complete ablation of ErbB2 function, for example, by gene
knockdown, is known to be lethal in ErbB2-dependent tumours8,
we deliberately used sublethal inhibitor concentrations to study
its effects on downstream signalling (Fig. 6c–e). As shown in
Fig. 6e, ARRY-380 diminished p-ErbB2 levels by 490%.
Under these conditions, p-ErbB3 and p-AKT levels were
markedly reduced, yet residual phosphorylation could be
detected. Importantly, the addition of trastuzumab to pretreated
cells induced a complete abolition of p-ErbB3 and p-AKT,
accompanied by an extensive cell death (Fig. 6d), reminiscent of
6L1G treatment in the absence of ARRY-380. These ﬁndings
further underline the importance of simultaneous inhibition
of ErbB2 activity and the obstruction of ErbB2–ErbB3
heterodimerization, which are apparently two different factors
that are both required for achieving a full apoptotic response.
We next carried out a knockdown of the ErbB3 receptor by
RNA interference. As shown in Fig. 7a, siHER3 substantially
attenuated ErbB3 expression and, consequently, p-ErbB3 levels.
Notably, AKT still remained partially phosphorylated in
siHER3-treated cells, reminiscent of the p-AKT rebound in
the presence of de-phosphorylated ErbB3 upon trastuzumab
treatment (Figs 1b and 4c). Consequently, ErbB3 knockdown
does not induce apoptosis efﬁciently in these cell lines (Fig. 7b–d;
Supplementary Fig. 4C–E) and, despite strongly impeding cell
proliferation, it did not achieve the full cytotoxic activity of 6L1G.
Nevertheless, it showed a synergistic effect when combined with
the concomitant inhibition of ErbB2 (Supplementary Fig. 4F).
These ﬁndings prompted us to analyse whether there is an
ErbB3-independent activation of the AKT pathway downstream
of ErbB2, even though ErbB2 itself does not possess p85 PI3K
docking sites. Therefore, we constructed homo-bivalent binding
agents GL4G (G3-L4-G3) or zH2-DHLX (zHer2-L2-DHLX),
directed either against ErbB2 ECD_4 or ECD_3, which potently
hyperactivated ErbB2 by promoting its homodimerization
(Fig. 7e). We found that both agents stimulate formation of
p-ErbB2 (Y877 and Y1222), p-AKT and p-ERK. Intriguingly, in
combination with knockdown of ErbB3, both GL4G and zH2-
DHLX rescued the p-AKT decrease, indicating the existence of an
alternative (ErbB3-independent) route linking ErbB2 receptor to
p-AKT activation. Consistently, growth inhibition by siHER3 was
rescued almost completely by both ErbB2 homodimerization
agents (Fig. 7f). Thus, both p-ErbB2 and p-ErbB3 are—despite
their mutual interdependence—individually contributing to the
survival of treated cancer cells by causing reactivation of AKT.
Small-GTPase RAS links ErbB2 with PI3K/AKT pathway. As
discussed above, ErbB2 dephosphorylation and dissociation of
Grb2 coincided with 6L1G-induced apoptosis (Fig. 1a). Since
Grb2 promotes SOS-mediated GDP/GTP exchange, we estimated
RAS activity by speciﬁcally detecting the GTP-bound form of
RAS in a GST-RBD (RAS-binding domain) pull-down assay. As
shown in Fig. 8a, 6L1G inhibited RAS in BT474 cells to a similar
extent as the farnesyltransferase (FT) inhibitor lonafarnib, a
potent blocker of RAS function. Trastuzumab did not suppress
RAS-GTP, owing to the inefﬁcient blockade of ErbB2. Active RAS
is known to directly interact and promote PI3K p110a activity
independently of p85 in some tumours39. 6L1G and lonafarnib
effectively impaired the interaction of RAS with p110a, whereas
RAS–p110a complex formation was even stimulated by
trastuzumab and correlated with the relative increment of
p-AKT (Fig. 8a). Thus, the ErbB2/Grb2/SOS/RAS pathway may
contribute to the activation of PI3K/AKT in the absence of ErbB3
and, consequently, to the rebound of AKT activity in the presence
of phosphorylated ErbB2, as it occurs under the conditions of
incomplete ErbB2 blockade by trastuzumab. Furthermore, since
PI3K integrates both the ErbB2/Grb2/SOS/RAS and ErbB3/p85
pathway, the ErbB2-overexpressing cancer cells become addicted
to the PI3K signalling hub, as manifested by increased
susceptibility to PI3K inhibitors (Supplementary Fig. 5A),
compared with ErbB3 inhibition (Fig. 7b).
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Consistent with these ﬁndings, lonafarnib as well as tipifarnib,
another RAS FT inhibitor, potentiated the cytotoxic activity of
trastuzumab (Fig. 8b), and the RAS inhibitor/trastuzumab
combination became as efﬁcient in inducing apoptosis as the
biparatopic agents (Fig. 8c). Importantly, the gain of cytotoxic
activity directly correlated with the inhibition of AKT
re-phosphorylation (Fig. 8d,e). Since tipifarnib as single agent
did not substantially inﬂuence p-AKT levels in ErbB2-over-
expressing cells, we deduce that the synergistic inhibition of
p-AKT by tipifarnib and trastuzumab was the consequence of
concurrent decoupling of AKT from p-ErbB3/p85/p110 by
trastuzumab together with RAS/p110 inhibition by tipifarnib.
To validate the signiﬁcance of RAS—p110a interaction for the
crosstalk between p-ErbB2 and PI3K, we made use of intracellular
RAS-binding proteins (Supplementary Fig. 5B), either blocking
the RAS-RBD binding interface (RAS104, RAS107) or not
interfering with the interaction with p110 (RAS109). Accordingly,
the cells carrying RAS104 and RAS107 showed signiﬁcantly
higher susceptibility to trastuzumab treatment than the cells with
no RAS interference (Fig. 8f). Furthermore, we silenced RAS
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expression using siRNAs against the two prevailing RAS isoforms
HRAS and KRAS39. As shown in Fig. 9a and Supplementary
Fig. 5C, the siHRAS/siKRAS cocktail efﬁciently downregulated
pan-RAS expression without substantial reduction of p-AKT
(except for SKBR3 cells, probably due to their high EGFR). Note
that HRAS/KRAS knockdown did not only block p-ERK, but it
also induced p-ErbB3 upregulation, possibly by interfering with
the AKT-FoxO3a-negative feedback. Importantly, trastuzumab
induced, in the background of suppressed RAS expression,
a sustained decrease of p-AKT, despite the incomplete blockade
of ErbB2. Consequently, RAS knockdown substantially
potentiated the anti-proliferative effect of trastuzumab-induced
ErbB3 inhibition (Fig. 9b; Supplementary Fig. 5D) and elicited
extensive cell death in all examined cell lines (Fig. 9c,
Supplementary Fig. 5E–H).
In agreement with these observations, the combination of
selective double knockdown of both ErbB3 and RAS by siRNA
treatment was sufﬁcient to block the p-AKT rebound occurring
after single ErbB3 knockdown (Fig. 9d). Furthermore,
hyperactivation of ErbB2 homodimers by GL4G, which is
sufﬁcient to reactive p-AKT in the absence of ErbB3, remained
without effect upon knockdown of RAS (Fig. 9d), thereby placing
RAS between ErbB2 and p-AKT.
Next we examined the direct linkage between ErbB2 and
RAS by selectively downregulating the adaptor protein Grb2
(Fig. 9e–g). The combination of siGrb2 and trastuzumab
b
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treatment prevented p-AKT rebound and, consequently, blocked
proliferation, induced cell cycle arrest and apoptosis. The RAS
pull-down assay revealed that siGrb2 as well as ARRY-380
treatment, particularly in combination with trastuzumab or
6L1G, led to a decline of the active form of RAS (Fig. 9h). In
contrast, RAS-GTP was induced upon homodimerization and
hyperphosphorylation of ErbB2; both GL4G and zH2-DHLX
potently stimulated active RAS, compensated the effect of
lonafarnib and ARRY-380 on RAS inhibition and gave rise to
an overall decrease of efﬁcacy of RAS, ErbB2 and AKT inhibition.
In summary, we found that in ErbB2-overexpressing breast
cancer cells the ErbB2/Grb2 interaction leads to the direct
activation of RAS which, in turn, mediates via interaction with
p110a the p-AKT rebound in response to an incomplete blockade
of ErbB2. Thus, we conclude that both routes to PI3K activation,
emanating from ErbB2/Grb2/RAS and ErbB3, must be inter-
rupted to achieve full anti-tumour response.
Finally, we investigated whether the described principles
underlying apoptosis induction after ErbB2/3 blockade shares a
common signalling mechanism with anoikis, a speciﬁc type of cell
death occurring during organogenesis of normal mammary
epithelium. Anoikis is known to be reverted by pathological
overexpression of ErbB2 (ref. 40) in conjunction with
hyperactivation of protein kinase Src, which may directly
interact with ErbB2 (ref. 41) and engage the Src/Erk/BIM
survival pathway42. To examine a potential involvement of Src,
we made use of selective Src inhibitors, siSRC or a dominant-
negative form of Src in 2D and 3D cultures of BT474 cells
(Supplementary Fig. 6A–D). Blockade of ErbB2/3 by the
biparatopic DARPin consistently attenuated Src activity
(Fig. 4c); conversely, the inhibition of Src alone or in
combination with trastuzumab does not trigger apoptosis in the
3D tumour model and does not induce PARP cleavage.
Accordingly, Src inhibition does not reduce p-AKT nor
prevents p-AKT rebound upon trastuzumab treatment in the
models investigated here.
In stark contrast, apoptosis also progressed in the presence of
active Src under conditions of simultaneous RAS inhibition
and an incomplete ErbB2 blockade (achieved by coincubation
with tipifarnib and trastuzumab (Supplementary Fig. 6A)).
In accordance, expression of constitutively active Src did not
lead to elevated p-AKT levels after the inhibition of ErbB3 and
RAS by the trastuzumab/tipifarnib combination or by 6L1G
(Supplementary Fig. 6E–G). Moreover, the Co-IP analysis of
ErbB2–Grb2 and ErbB2–Src complexes under several treatment
conditions revealed that Src inhibition did not affect integrity of
the ErbB2–Grb2 complexes and only had a small effect on the
phosphorylation of ErbB2 (Supplementary Fig. 6H).
Altogether, this argues for the existence of two distinct
apoptotic programmes that are executed (i) upon complete
ErbB2 blockade in ErbB2-addicted tumours and (ii) during
anoikis in the development of normal mammary epithelium
without ErbB2 addiction. The latter employs indeed primarily the
Src/Erk/BIM axis. By contrast, in ErbB2-addicted tumours
induction of apoptosis occurs independently of Src status. In
conclusion, as shown in this study, apoptosis necessitates
complete and sustained blockade of the PI3K/AKT pathway
for preventing p-AKT rebound, and thus requires an intervention
at both the ErbB3/p85 and the ErbB2/RAS/p110 routes feeding
into PI3K/AKT.
Discussion
Although trastuzumab- and TKI-treatment provide clinical
beneﬁt with respect to improved progression-free survival, the
persisting problem in therapy is that even patients who
initially respond to these substances invariably develop resistance
while progressing towards advanced disease23. Antagonistic
monoclonal antibodies and small-molecule inhibitors of
receptor tyrosine kinases or intracellular pro-survival
pathways can lower the apoptotic threshold and thus increase
the tumour-speciﬁc cytotoxicity of chemotherapeutics.
Nevertheless, an effective treatment of ErbB2-overexpressing
breast tumours necessitates strategies that not only rely on
rapid induction of cell death, but also counter the tumour
escape mechanisms leading to a long-term adaptation to the
treatment. Therefore, such agents should ideally interfere with the
multiple compensatory mechanisms that would otherwise
minimize the drug potency by generating a new steady state
of the oncogenic network27. By targeting two distinct epitopes of
ErbB2 with appropriately designed biparatopic binding
DARPins31 that completely disengage ErbB2 from its signalling
network, we developed powerful agents with cytotoxic activity
against ErbB2-addicted breast cancer cells and no measurable
effects on normal cells with physiological ErbB2 levels. The
cytotoxic activity was overall retained in cells with an additional
p53 deﬁciency or low PTEN expression and even in cells bearing
PIK3CA activating mutations, these biparatopic anti-ErbB2
agents still displayed signiﬁcant anti-proliferative activity,
although the pro-apoptotic activity has been signiﬁcantly
reduced, indicating the central role of PI3K/AKT pathway in
mediating resistance to ErbB2 blockade.
For optimal antitumor effects of therapeutic agents acting on
overexpressed ErbB2, a sustained and complete inhibition of ErbB3
phosphorylation and the downstream signalling to PI3K/AKT is
required. As a consequence of the relieved negative feedback loop
operating in tumours with elevated PI3K/AKT signalling, however,
there is typically upregulation and marked increase of ErbB3 in the
plasma membrane, accompanied by re-phosphorylation of
ErbB3 due to residual ErbB2 activity22,43. Thus, ErbB3 signalling
is ‘buffered’ as long as inhibition of the ErbB2 kinase is incomplete,
and this applies particularly to the small-molecule kinase
inhibitors. Such adaptive capabilities of the ErbB oncogenic
signalling network reveal fundamental limitations of
monotherapy for inhibiting feedback-regulated pathways
(Fig. 10a–c). Therefore, alternative strategies are required to
silence oncogenic ErbB2/3 signalling effectively.
In the present study, we describe a new adaptive response
leading to reactivation of PI3K/AKT signalling during trastuzumab
treatment, which occurs even under circumstances when ErbB3
remains de-phosphorylated as a consequence of ErbB2 blockade
(Fig. 10b). This signalling pathway, bypassing ErbB3, operates in
the majority of examined ErbB2-overexpressing breast cancer cell
lines, and it is clearly distinct from other mechanisms of adaptive
resistance to trastuzumab such as upregulation of ErbB family
receptors and cognate RTKs, or increased expression of the
respective ligands27,44. We showed that PI3K/AKT evades
sustained inhibition, because trastuzumab fails to induce
dephosphorylation of ErbB2 itself. Notably, the lack of ErbB2
dephosphorylation had been previously postulated to be one of the
key reasons why a longstanding trastuzumab treatment leads to
development of acquired resistance in ErbB2-addicted cells10. Yet
the precise compensatory mechanisms leading to reactivation of
PI3K/PKB in the absence of functional ErbB2–ErbB3 complexes
had not been understood.
In fact, we have now identiﬁed the ErbB2–RAS interaction as a
crucial regulatory switch determining whether the AKT
pathway becomes inhibited persistently upon ErbB2/3 targeting
or only transiently with a subsequent reactivation. The
activation of the PI3K pathway via RAS is well characterized;
Grb2, an adaptor protein binding the phosphorylated tail of
ErbB2, associates with SOS, which then activates RAS that, in
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turn, triggers allosteric activation of p110a independently of
p85 (ref. 45). Indeed, p110a is a critical effector for RAS-
driven tumorigenesis in several tumour types and animal
tumour models46. Although ras mutations are rare in breast
cancer, aberrant activation of the RAS protein and its
downstream effectors is common and occurs as a result of
ampliﬁcation of KRAS47. Moreover, ras mutations are rarely
found together with PI3K mutations in breast tumours39, again
indicating engagement of overlapping signalling pathways during
tumorigenesis.
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Figure 10 | Model of induction of apoptosis and adaptive resistance in response to ErbB2 blockade. (a) Overexpression of ErbB2 is sufﬁcient to activate
ErbB2 and ErbB3 in the absence of ligands and drives tumour growth predominantly via the ErbB2/ErbB3/PI3K/AKT signalling axis. This signalling route
constitutively suppresses negative feedback regulation between AKT and ErbB3, which is however relieved upon blockade of ErbB2/3 receptors or the
downstream signalling pathways. (b) Trastuzumab treatment induces partial ErbB2 blockade by selectively interfering with the ligand-independent ErbB2/
ErbB3 heterodimers, thereby uncoupling ErbB3 from PI3K/AKTreactivation. Here we identiﬁed a novel adaptation response that emanates from ErbB2/RAS
and bypasses ErbB3 for the activation of PI3K/AKTsignalling. (c) Biparatopic DARPins obstruct all ligand-dependent and ligand-independent complexes of
ErbB2. Such a pan-ErbB2 inhibition blocks PI3K/AKT signalling cascade and consecutive adaptive responses, leading to a stable OFF state of the ErbB
oncogenic network. Consequently, intrinsic apoptosis is induced which prevents emergence of adaptive resistance.
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There is an increasing number of observations hinting at the
possible role of aberrant RAS signalling also in the emergence
of innate and acquired resistance against ErbB2 targeting.
For instance, modiﬁed SKBR3 cells overexpressing HRAS or
harbouring the oncogenic allele HRAS V12 displayed reduced
susceptibility to lapatinib, in analogy to what was observed with
activating PIK3CA mutations or the constitutively active form of
AKT48. Moreover, in vitro and in silico evaluations have
uncovered ras mutation as a dominant predictor of resistance
to PI3K inhibitors in cancers of different origin including
breast tumours overexpressing ErbB2 (refs 49–51). Thus,
although the clinical relevance of the RAS-mediated resistance
against ErbB2 blockade still needs to be proven, promising results
from phase I studies of the RAS FT inhibitor lonafarnib,
administered in combination with trastuzumab plus paclitaxel—
showing a respectable objective response rate of 58% in treatment
of advanced ErbB2-overexpressing breast cancer—or regimens
combining AKT inhibitor MK2206 with trastuzumab, underscore
the potential of therapeutic intervention at the RAS-PI3K-AKT
axis in the treatment of ErbB2-addicted breast cancers52,53.
In the absence of external perturbations, the growth of ErbB2-
dependent tumours occurs with operational AKT-ErbB3-negative
feedback, that is, leading to lower ErbB3 levels, as a result of
continued stimulation of AKT. Therefore, RAS inhibitor treatment,
which interferes with the RAS-PI3K/AKT crosstalk, induces relief
of this feedback and leads to upregulation of ErbB3, gradual re-
phosphorylation of AKT and, consequently, to desensitization to
RAS inhibitors, since then the relative ﬂux through the ErbB3/
PI3K/AKT pathway increases. However, if RAS inhibitors are
combined with agents antagonizing the ErbB3 phosphorylation,
such as trastuzumab, the outcome of RAS inhibition becomes
substantially potentiated and comparable to the cytotoxic effects of
RAS inhibitors observed for RAS-driven tumours.
As outlined above, the dephosphorylation of ErbB3 receptor,
even if persisting for periods of days, is not sufﬁcient to induce
complete and sustained inhibition of AKT, explaining why all
currently available anti-ErbB3 compounds failed to induce
apoptosis as single agents13,14. Moreover, we and others showed
that even the ErbB3 depletion by siRNA was not enough to elicit
an apoptotic response in ErbB2-dependent tumours, although it
potently inhibited proliferation of tumour cells21. Hence, the
targeting of ErbB3 alone is not sufﬁcient despite the indisputable
role of ErbB3 in ErbB2-driven oncogenesis. The same accounts for
prototypical ErbB2-targeting agents such as trastuzumab or
pertuzumab, which only exert their effect on decoupling of
ErbB3 from ErbB2, but leaving the phosphorylated ErbB2
unaffected (Fig. 7a). On the other hand, TKIs targeting solely
ErbB2 usually suffer from the aforementioned reactivation of
ErbB3, due to relief of the negative feedback with AKT, so that
ErbB2/3 signalling is buffered against a nearly two-log inhibition of
ErbB2 catalytic activity43.
The close mechanistic linkage between ErbB2 and ErbB3 thus
entails the necessity to inhibit both ErbB2 and ErbB3 for an
efﬁcient targeting and silencing of ErbB2/3 signalling (Fig. 10c).
This can be achieved by disassembly of all ErbB2-dependent
complexes in a pan-ErbB approach, accompanied by inactivation
of the receptor tyrosine kinases, as described in this work. By
targeting two distinct epitopes of ErbB2 with appropriately
designed biparatopic DARPins31 that completely disengage
ErbB2 from the signalling network.
In conclusion, our study has untangled the mechanism
underlying cancer cell-speciﬁc apoptotic response in ErbB2-
addicted cells, revisited the individual roles of ErbB2 and ErbB3
receptors in tumour targeting and deﬁned a new, as yet
disregarded adaptive response operating via RAS-PI3K/AKT
crosstalk, which leads to a desensitization towards current
therapeutics. The new insights arising from this study can thus
translate to improvement of current therapeutic modalities
and aid in the rational design of a novel class of cell-speciﬁc
extracellular receptor-targeting therapeutics with improved
tumoricidal activity, low side effects and potential to avoid
development of drug resistance. Nonetheless, an optimal targeting
format of the biparatopic anti-ErbB2 DARPins31, with improved
PK/PD proﬁle while retaining the high pro-apoptotic activity, is
still to be deﬁned in ongoing in vivo studies. Furthermore, it will
have to be ascertained in future preclinical and clinical
experiments whether the induction of apoptosis in tumours
during DARPin monotherapy is rapid and potent enough in
order to eliminate cells that otherwise would acquire new
cancerous mutations, bearing, for example, constitutively active
PI3K, and to what degree cells from heterogeneous breast
tumours, harbouring preexisting mutations, would have a
selective growth advantage. We believe, however, that the
structure- and mechanism-based engineering of ErbB2 ligands,
which potently induce cell-speciﬁc apoptosis and diminish
adaptive response, may provide a foothold for development of
truly effective combination therapies to combat resistant tumours.
Methods
XTT cell proliferation assay. Cells were seeded in 96-well plates at a density of
2,000–10 000 cells per cm2 predetermined for each cell line. After 24 h, DARPins or
mAbs were added in triplicates, and cells were incubated for another 96 h, unless
indicated otherwise. In XTT assays (Cell proliferation kit II; Roche), A450 was
measured and expressed as % untreated control.
Clonogenic assay. BT474 cells were treated for 4 days with 100 nM of anti-ErbB2
agents, collected by trypsinization, washed 3 with complete culture medium,
serially diluted and seeded in fresh 6-well plates. Colonies were grown for 5 weeks,
and the medium was refreshed twice per week. Colonies were ﬁxed with
glutaraldehyde, stained with crystal violet and the colony number was determined
in triplicate for each single dilution.
3D growth assay. BT474 cells were seeded overnight at 1 104 cells per cm2 on
top of Matrigel (BD Biosciences). Cells were treated with 100 nM targeting agents
in the absence or presence of 1 nM HRG, and the medium was refreshed every 3
days. Growth and morphogenesis of acini were analysed after 12 days by a
modiﬁed XTT assay or by counting budding sites for 3 times 100 acini per
treatment, respectively.
Flow cytometry: cell cycle, TUNEL and annexin V assays. Cells were seeded at
5,000 to 10,000 cells per cm2 under standard conditions 24 h prior to treatment with
100 nM of anti-ErbB2 agents. After 3 days, cells were collected by trypsinization and
ﬁxed in 70% EtOH or in 4% paraformaldehyde for propidium iodide (20mgml 1;
2 Kunitz units per ml of RNAse) or TUNEL labelling (In situ cell death detection kit,
Roche), respectively. The AnnexinV/PI assay was performed with non-ﬁxed cells
treated for 2 days (ApoDETECT Kit; Life Technologies). The cell cycle distribution
and apoptosis rate were quantiﬁed with FlowJo software.
Mouse xenograft studies. Eight-week-old female SCID beige mice were obtained
from Charles River Laboratories and implanted with 0.025-mg, 90-day release,
17b-estradiol pellets (Innovative Research of America). After 2 days, 2 106 BT474
cells were resuspended in 100ml of PBS and 1:1 mixture with Matrigel was
inoculated orthotopically into the mammary gland fat pad. Once tumours reached a
volume of 200mm3, 6–8 animals were selected and randomly assigned into four
treatment cohorts with equal average tumour volumes. The DARPins were admi-
nistered by i.v. injection three times per week in a total of nine doses of 20mg kg 1.
Tumour dimensions were serially measured every 2 days, and volumes calculated
using the formula V¼ (LW2)/2, where V¼ volume, L¼ length and W¼width.
For immunohistochemistry, animals were perfused and tumours were resected on
day 14 after initiation of treatment (Supplementary Experimental Procedures).
Bioimaging studies were performed after single i.p. injection of 1mgkg 1 DARPin
on an IVIS 100 instrument (Caliper Life Sciences), and biodistribution was
quantiﬁed with Living Image software. All mice were maintained and handled under
aseptic conditions. The studies were approved by the Cantonal Veterinary Ofﬁce
(Zurich, Switzerland). Housing and experimental procedures were in accordance
with the Swiss animal protection law (Supplementary Experimental Procedures).
Statistical analysis. All data are expressed as means±standard deviation (s.d.)
unless indicated otherwise. The statistical analysis for two-group comparisons was
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performed in the following order: (i) Student’s t-test for normally distributed
samples with equal variance, (ii) Welch t-test for normally distributed samples with
unequal variance (iii) Mann–Whitney Rank Sum Test for non-normally distributed
samples. Next, we have included multiple sample comparisons versus control
analysis by ANOVA followed by post hoc Dunnett’s test. Signiﬁcance was
established at the Pr0.05; 0.01 and 0.001 level, as indicated in the ﬁgures.
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